Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens

Vaccine

Volumn 16, Issue 18, 1998, Pages 1711-1717

  Fu, Tong Ming ^a   Guan, Liming ^a   Friedman, Arthur ^a   Ulmer, Jeffrey B ^a,b   Liu, Margaret A ^a,b   Donnelly, John J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antibody; CTC precursor; Influenza; Mice; Vaccine

Indexed keywords

DNA VACCINE; PROTEASOME; UBIQUITIN; VIRUS NUCLEOPROTEIN;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ARTICLE; CELL CULTURE; CONJUGATION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANIMALS; ANTIGENS, VIRAL; CELLS, CULTURED; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; NUCLEOPROTEINS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; UBIQUITINS; VACCINES, DNA;

EID: 0032213351     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00134-0     Document Type: Article

References (32)

1. 1 Ulmer, J.B., Donnelly, J.J. and Parker, S.E. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259, 1745-1749.
2. 2 Bender, B.S., Ulmer, J.B., DeWitt, C.M. et al. Immunogenicity and efficacy of DNA vaccines encoding influenza proteins in aged mice. Vaccine (in press).
3. 3 Germain, R.N. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994, 76, 287-299.
4. 4 Yewdell, J.W. and Bennink, J.R. Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. Adv. Immunol. 1992, 52, 1-123.
5. 5 Martinez, C.K. and Monaco, J.J. Homology of proteasome subunits to a major histocompatibility complex-linked LMP gene. Nature 1991, 353, 664-667.
6. 6 Ortiz-Navarrete, V, Seelig, A., Gernold, M., Frentzel, S., Kloetzel, P.M. and Hammerling, G.J. Subunit of the '20S' proteasome (multicatalytic proteinase) encoded by the major histocompatibility complex. Nature 1991, 353, 662-664.
7. 7 Fehling, H.J., Swat, W. and Laplace, C. et al. MHC class I expression in mice lacking the proteasome subunit LMP-7. Science 1994, 265, 1234-1238.
8. 8 Van Kaer, L., Ashton-Rickardt, P.G. and Eichelberger, M. et al. Altered peptidase and viral-specific T cell response in LMP2 mutant mice. Immunity 1994, 1, 533-542.
9. 9 Grant, E.P., Michalek, M.T., Goldberg, A.L. and Rock, K.L. Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. J. Immunol. 1995, 155, 3750-3758.
10. 10 Rock, K.L., Gramm, G. and Rothstein, L. et al. Inhibitors of the proteasome block degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994, 78, 761-771.
11. 11 Niedermann, G., Butz, S. and Ihlenfeldt, H.G. et al. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity 1995, 2, 289-299.
12. 12 Tobery, T.W. and Siliciano, R.F. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J. Exp. Med. 1997, 185, 909-920.
13. 13 Townsend, A., Bastin, J. and Gould, K. et al. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J. Exp. Med. 1988, 168, 1211-1224.
14. 14 Fu, T.-M., Friedman, A., Ulmer, J.B., Liu, M.A. and Donnelly, J.J. Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. J. Virol. 1997, 71, 2715-2721.
15. 15 Corr, M., Lee, D.J., Carson, D.A. and Tighe, H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J. Exp. Med. 1996, 184, 1555-1560.
16. 16 Fu, T.-M., Ulmer, J.B. and Caulfield, M.J. et al. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol. Med. 1997, 3, 362-371.
17. 17 Ulmer, J.B., Deck, R.R., DeWitt, C.M., Donnelly, J.J. and Liu, M.A. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology 1996, 89, 59-67.
18. 18 Montgomery, D.L., Shiver, J.W. and Keander, K.R. et al. Heterologous and homologous protection against influenza virus A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol. 1993, 12, 777-783.
19. 19 Sambrook, J., Fritsch, E.F. and Maniatis, T. Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
20. 20 Fu, T.-M., Bonneau, R.H. and Epler, M. et al. Inducation and persistence of a cytotoxic T lymphocyte (CTL) response against a herpes simplex virus-specific CTL epitope expressed in a cellular protein. Virology 1996, 222, 269-274.
21. 21 Bonneau, R.H. and Jennings, S.R. Herpes simplex virus-specific cytolytic T lymphocytes restricted to a normally low responder H-2 allele are protective in vivo. Virology 1990, 174, 599-604.
22. 22 Jentsch, S. and Schlenker, S. Selective protein degradation: a journey's end within the proteasome. Cell 1995, 82, 881-884.
23. 23 Bachmair, A., Finley, D. and Varshavsky, A. In vivo half-life of a protein is a function of its amino-terminal residue. Science 1986, 234, 179-186.
24. 24 Johnson, E.S., Bartel, B., Seufert, W. and Varshavsky, A. Ubiquitin as a degradation signal. EMBO J. 1992, 11, 497-505.
25. 25 Groettrup, M., Ruppert, T. and Kuehn, L. et al. The interferon-γ-inducible 11S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20S proteasome in vitro. J. Biol. Chem. 1995, 270, 23808-23815.
26. 26 Cox, J.H., Galardy, P., Bennink, J.R. and Yewdell, J.W. Presentation of endogenous and exogenous antigens is not affected by inactivation of E1 ubiquitin-activating enzyme in temperature-sensitive cell lines. J. Immunol. 1995, 154, 511-519.
27. 27 Vinitsky, A., Anton, L.C., Snyder, H.L., Orlowski, M., Bennink, J.R. and Yewdell, J.W. The generation of MHC class I-associated peptides is only partially inhibited by proteasome inhibitors: involvement in nonproteasomal cytosolic proteases in antigen processing?. J. Immunol. 1997, 159, 554-564.
28. 28 Yellen-Shaw, A.J., Wherry, E.J., Dubois, G.C. and Eisenlohr, L.C. Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length viral protein. J. Immunol. 1997, 158, 3227-3234.
29. 29 Fu, T.-M., Mylin, L.M., Schell, T.D. et al. Flanking sequences modify the antigenicity and immunogenicity of an immunorecessive MHC class I-restricted tumor antigen-derived peptide. J. Virol. (in press).
30. 30 Arnold, D., Faath, S., Rammensee, H.-G. and Schild, H. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J. Exp. Med. 1995, 182, 885-889.
31. 31 Suto, R. and Srivastava, P.K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 1995, 269, 1585-1588.
32. 32 Rodriguez, F., Zhang, J. and Whitton, J.L. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Virology 1997, 71, 8497-8503.